1
|
Samarin J, Fabrowski P, Kurilov R, Nuskova H, Hummel-Eisenbeiss J, Pink H, Li N, Weru V, Alborzinia H, Yildiz U, Grob L, Taubert M, Czech M, Morgen M, Brandstädter C, Becker K, Mao L, Jayavelu AK, Goncalves A, Uhrig U, Seiler J, Lyu Y, Diederichs S, Klingmüller U, Muckenthaler M, Kopp-Schneider A, Teleman A, Miller AK, Gunkel N. Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs. Redox Biol 2023; 62:102639. [PMID: 36958250 PMCID: PMC10053401 DOI: 10.1016/j.redox.2023.102639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Revised: 02/13/2023] [Accepted: 02/14/2023] [Indexed: 02/25/2023] Open
Abstract
Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of "antioxidant-capacity" biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive cells, rendering them susceptible to multiple redox-targeting and ferroptosis-inducing drugs. Contrary to expectation, constitutively low ACB expression was not associated with an increased steady state level of reactive oxygen species (ROS) but a high level of nitric oxide, which is required to sustain high replication rates. Using ACBs, we identified cancer entities with a high percentage of patients with favorable ACB expression pattern, making it likely that more responders to ROS-inducing drugs could be stratified for clinical trials.
Collapse
Affiliation(s)
- Jana Samarin
- Cancer Drug Development, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Piotr Fabrowski
- Cancer Drug Development, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Roman Kurilov
- Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Hana Nuskova
- Cancer Drug Development, German Cancer Research Center (DKFZ), Heidelberg, Germany; Division of Signal Transduction in Cancer and Metabolism, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - Hannelore Pink
- Cancer Drug Development, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Nan Li
- Somatic Evolution and Early Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Vivienn Weru
- Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Hamed Alborzinia
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Umut Yildiz
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Laura Grob
- Cancer Drug Development, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Minerva Taubert
- Cancer Drug Development, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Marie Czech
- Cancer Drug Development, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Michael Morgen
- Cancer Drug Development, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Christina Brandstädter
- Biochemistry and Molecular Biology, Interdisciplinary Research Center, Justus Liebig University, Giessen, Germany
| | - Katja Becker
- Biochemistry and Molecular Biology, Interdisciplinary Research Center, Justus Liebig University, Giessen, Germany
| | - Lianghao Mao
- Proteomics and Cancer Cell Signaling Group, CCU Pediatric Leukemia, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Ashok Kumar Jayavelu
- Proteomics and Cancer Cell Signaling Group, CCU Pediatric Leukemia, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Angela Goncalves
- Somatic Evolution and Early Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Ulrike Uhrig
- Chemical Biology Core Facility, EMBL, Heidelberg, Germany
| | - Jeanette Seiler
- Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Yanhong Lyu
- Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany; Division of Cancer Research, Department of Thoracic Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK) - Partner Site Freiburg, Freiburg, Germany
| | - Sven Diederichs
- Division of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany; Division of Cancer Research, Department of Thoracic Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK) - Partner Site Freiburg, Freiburg, Germany
| | - Ursula Klingmüller
- Division of Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany
| | - Martina Muckenthaler
- Department of Pediatric Hematology, Oncology and Immunology, University of Heidelberg, Heidelberg, Germany
| | | | - Aurelio Teleman
- Division of Signal Transduction in Cancer and Metabolism, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Aubry K Miller
- Cancer Drug Development, German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Nikolas Gunkel
- Cancer Drug Development, German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany.
| |
Collapse
|
2
|
Morgen M, Fabrowski P, Amtmann E, Gunkel N, Miller AK. Inclusion Complexes of Gold(I)-Dithiocarbamates with β-Cyclodextrin: A Journey from Drug Repurposing towards Drug Discovery. Chemistry 2021; 27:12156-12165. [PMID: 34114261 PMCID: PMC8456977 DOI: 10.1002/chem.202101366] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Indexed: 11/11/2022]
Abstract
The gold(I)-dithiocarbamate (dtc) complex [Au(N,N-diethyl)dtc]2 was identified as the active cytotoxic agent in the combination treatment of sodium aurothiomalate and disulfiram on a panel of cancer cell lines. In addition to demonstrating pronounced differential cytotoxicity to these cell lines, the gold complex showed no cross-resistance in therapy-surviving cancer cells. In the course of a medicinal chemistry campaign on this class of poorly soluble gold(I)-dtc complexes, >35 derivatives were synthesized and X-ray crystallography was used to examine structural aspects of the dtc moiety. A group of hydroxy-substituted complexes has an improved solubility profile, and it was found that these complexes form 2 : 1 host-guest inclusion complexes with β-cyclodextrin (CD), exhibiting a rarely observed "tail-to-tail" arrangement of the CD cones. Formulation of a hydroxy-substituted gold(I)-dtc complex with excess sulfobutylether-β-CD prevents the induction of mitochondrial reactive oxygen species, which is a major burden in the development of metallodrugs.
Collapse
Affiliation(s)
- Michael Morgen
- Cancer Drug Development Group (A390)German Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120HeidelbergGermany
| | - Piotr Fabrowski
- Cancer Drug Development Group (A390)German Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120HeidelbergGermany
| | - Eberhard Amtmann
- Cancer Drug Development Group (A390)German Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120HeidelbergGermany
| | - Nikolas Gunkel
- Cancer Drug Development Group (A390)German Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120HeidelbergGermany
- German Cancer Consortium (DKTK)69120HeidelbergGermany
| | - Aubry K. Miller
- Cancer Drug Development Group (A390)German Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120HeidelbergGermany
- German Cancer Consortium (DKTK)69120HeidelbergGermany
| |
Collapse
|
3
|
Herbst-Gervasoni CJ, Steimbach RR, Morgen M, Miller AK, Christianson DW. Structural Basis for the Selective Inhibition of HDAC10, the Cytosolic Polyamine Deacetylase. ACS Chem Biol 2020; 15:2154-2163. [PMID: 32659072 DOI: 10.1021/acschembio.0c00362] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The cytosolic class IIb histone deacetylase HDAC10 is an emerging target for drug design. As an inducer of autophagy, its selective inhibition suppresses the autophagic response that otherwise attenuates the efficacy of cytotoxic cancer chemotherapy drugs. HDAC10 is a zinc-dependent polyamine deacetylase exhibiting maximal catalytic activity against N8-acetylspermidine. As revealed in the structure of Danio rerio (zebrafish) HDAC10, two conserved structural motifs direct this narrow substrate specificity: a 310 helix containing the P(E,A)CE motif that sterically constricts the active site and an electrostatic "gatekeeper," E274, that confers selectivity for cationic polyamine substrates. To accelerate drug design efforts targeting human HDAC10, we now report the preparation of "humanized" zebrafish HDAC10 in which two amino acid substitutions, A24E and D94A, yield an active site contour more similar to that of human HDAC10. X-ray crystal structures of this HDAC10 variant complexed with Tubastatin A and indole analogues bearing pendant tertiary amines reveal that inhibitors capable of hydrogen bonding with gatekeeper E274 exhibit high affinity and selectivity for HDAC10 over HDAC6 (the other class IIb isozyme). Moreover, these structures reveal that the P(E,A)CE motif helix can shift by up to 2 Å to accommodate the binding of bulky inhibitors. Thus, slender polyamine-like inhibitor structures are not exclusively required for selective, high affinity binding to HDAC10. Indeed, the flexibility of the P(E,A)CE motif helix could conceivably enable the binding of certain protein substrates.
Collapse
Affiliation(s)
- Corey J. Herbst-Gervasoni
- Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323, United States
| | - Raphael R. Steimbach
- Biosciences Faculty, University of Heidelberg, 69120 Heidelberg, Germany
- Cancer Drug Development Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Michael Morgen
- Cancer Drug Development Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Aubry K. Miller
- Cancer Drug Development Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
| | - David W. Christianson
- Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323, United States
| |
Collapse
|
4
|
Morgen M, Steimbach RR, Géraldy M, Hellweg L, Sehr P, Ridinger J, Witt O, Oehme I, Herbst‐Gervasoni CJ, Osko JD, Porter NJ, Christianson DW, Gunkel N, Miller AK. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors. ChemMedChem 2020; 15:1163-1174. [PMID: 32348628 PMCID: PMC7335359 DOI: 10.1002/cmdc.202000149] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Revised: 04/23/2020] [Indexed: 12/22/2022]
Abstract
We report the synthesis and evaluation of a class of selective multitarget agents for the inhibition of HDAC6, HDAC8, and HDAC10. The concept for this study grew out of a structural analysis of the two selective inhibitors Tubastatin A (HDAC6/10) and PCI-34051 (HDAC8), which we recognized share the same N-benzylindole core. Hybridization of the two inhibitor structures resulted in dihydroxamic acids with benzyl-indole and -indazole core motifs. These substances exhibit potent activity against HDAC6, HDAC8, and HDAC10, while retaining selectivity over HDAC1, HDAC2, and HDAC3. The best substance inhibited the viability of the SK-N-BE(2)C neuroblastoma cell line with an IC50 value similar to a combination treatment with Tubastatin A and PCI-34051. This compound class establishes a proof of concept for such hybrid molecules and could serve as a starting point for the further development of enhanced HDAC6/8/10 inhibitors.
Collapse
Affiliation(s)
- Michael Morgen
- Cancer Drug Development GroupGerman Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120HeidelbergGermany
| | - Raphael R. Steimbach
- Cancer Drug Development GroupGerman Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120HeidelbergGermany
- Faculty of BiosciencesUniversity of Heidelberg69120HeidelbergGermany
| | - Magalie Géraldy
- Cancer Drug Development GroupGerman Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120HeidelbergGermany
| | - Lars Hellweg
- Cancer Drug Development GroupGerman Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120HeidelbergGermany
| | - Peter Sehr
- Chemical Biology Core FacilityEuropean Molecular Biology Laboratory (EMBL)69117HeidelbergGermany
| | - Johannes Ridinger
- Hopp Children's Cancer Center Heidelberg (KiTZ)69120HeidelbergGermany
- Clinical Cooperation Unit Pediatric OncologyGerman Cancer Research Center (DKFZ)69120HeidelbergGermany
- Department of Pediatric OncologyHematology and ImmunologyUniversity Hospital Heidelberg69120HeidelbergGermany
| | - Olaf Witt
- Hopp Children's Cancer Center Heidelberg (KiTZ)69120HeidelbergGermany
- Clinical Cooperation Unit Pediatric OncologyGerman Cancer Research Center (DKFZ)69120HeidelbergGermany
- Department of Pediatric OncologyHematology and ImmunologyUniversity Hospital Heidelberg69120HeidelbergGermany
- German Cancer Consortium (DKTK)69120HeidelbergGermany
| | - Ina Oehme
- Hopp Children's Cancer Center Heidelberg (KiTZ)69120HeidelbergGermany
- Clinical Cooperation Unit Pediatric OncologyGerman Cancer Research Center (DKFZ)69120HeidelbergGermany
- Department of Pediatric OncologyHematology and ImmunologyUniversity Hospital Heidelberg69120HeidelbergGermany
| | - Corey J. Herbst‐Gervasoni
- Roy and Diana Vagelos LaboratoriesDepartment of ChemistryUniversity of PennsylvaniaPhiladelphiaPA 19104-6323USA
| | - Jeremy D. Osko
- Roy and Diana Vagelos LaboratoriesDepartment of ChemistryUniversity of PennsylvaniaPhiladelphiaPA 19104-6323USA
| | - Nicholas J. Porter
- Roy and Diana Vagelos LaboratoriesDepartment of ChemistryUniversity of PennsylvaniaPhiladelphiaPA 19104-6323USA
| | - David W. Christianson
- Roy and Diana Vagelos LaboratoriesDepartment of ChemistryUniversity of PennsylvaniaPhiladelphiaPA 19104-6323USA
| | - Nikolas Gunkel
- Cancer Drug Development GroupGerman Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120HeidelbergGermany
- German Cancer Consortium (DKTK)69120HeidelbergGermany
| | - Aubry K. Miller
- Cancer Drug Development GroupGerman Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120HeidelbergGermany
- German Cancer Consortium (DKTK)69120HeidelbergGermany
| |
Collapse
|
5
|
Géraldy M, Morgen M, Sehr P, Steimbach RR, Moi D, Ridinger J, Oehme I, Witt O, Malz M, Nogueira MS, Koch O, Gunkel N, Miller AK. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated. J Med Chem 2019; 62:4426-4443. [PMID: 30964290 DOI: 10.1021/acs.jmedchem.8b01936] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The discovery of isozyme-selective histone deacetylase (HDAC) inhibitors is critical for understanding the biological functions of individual HDACs and for validating HDACs as drug targets. The isozyme HDAC10 contributes to chemotherapy resistance and has recently been described to be a polyamine deacetylase, but no studies toward selective HDAC10 inhibitors have been published. Using two complementary assays, we found Tubastatin A, an HDAC6 inhibitor, to potently bind HDAC10. We synthesized Tubastatin A derivatives and found that a basic amine in the cap group was required for strong HDAC10 binding. HDAC10 inhibitors mimicked knockdown by causing dose-dependent accumulation of acidic vesicles in a neuroblastoma cell line. Furthermore, docking into human HDAC10 homology models indicated that a hydrogen bond between a cap group nitrogen and the gatekeeper residue Glu272 was responsible for potent HDAC10 binding. Taken together, our data provide an optimal platform for the development of HDAC10-selective inhibitors, as exemplified with the Tubastatin A scaffold.
Collapse
Affiliation(s)
| | | | - Peter Sehr
- Chemical Biology Core Facility , European Molecular Biology Laboratory , 69117 Heidelberg , Germany
| | | | | | - Johannes Ridinger
- Biosciences Faculty , University of Heidelberg , 69120 Heidelberg , Germany.,Hopp Children's Cancer Center Heidelberg (KiTZ) , 69120 Heidelberg , Germany.,Department of Pediatric Oncology, Hematology and Immunology , University Hospital Heidelberg , 69120 Heidelberg , Germany
| | - Ina Oehme
- Hopp Children's Cancer Center Heidelberg (KiTZ) , 69120 Heidelberg , Germany.,German Cancer Consortium (DKTK) , 69120 Heidelberg , Germany
| | - Olaf Witt
- Hopp Children's Cancer Center Heidelberg (KiTZ) , 69120 Heidelberg , Germany.,Department of Pediatric Oncology, Hematology and Immunology , University Hospital Heidelberg , 69120 Heidelberg , Germany.,German Cancer Consortium (DKTK) , 69120 Heidelberg , Germany
| | | | - Mauro S Nogueira
- Faculty of Chemistry and Chemical Biology , TU Dortmund University , 44227 Dortmund , Germany
| | - Oliver Koch
- Faculty of Chemistry and Chemical Biology , TU Dortmund University , 44227 Dortmund , Germany
| | - Nikolas Gunkel
- German Cancer Consortium (DKTK) , 69120 Heidelberg , Germany
| | - Aubry K Miller
- German Cancer Consortium (DKTK) , 69120 Heidelberg , Germany
| |
Collapse
|
6
|
Stewart A, Yates I, Mudie D, Pivette P, Goodwin A, Sarmiento A, Winter M, Morgen M, Vodak D. Mechanistic Study of Belinostat Oral Absorption From Spray-Dried Dispersions. J Pharm Sci 2018; 108:326-336. [PMID: 30300620 DOI: 10.1016/j.xphs.2018.09.031] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Revised: 09/14/2018] [Accepted: 09/28/2018] [Indexed: 02/03/2023]
Abstract
Spray-dried dispersions (SDDs) are an important technology for enhancing the oral bioavailability of poorly water-soluble drugs. To design an effective oral SDD formulation, the key rate-determining step(s) for oral drug absorption must be understood. This work combined in vivo and in vitro tests with in silico modeling to identify the rate-determining steps for oral absorption of belinostat SDDs made with 3 different polymers (PVP K30, PVP VA64, and HPMCAS-M). The goal was developing a belinostat SDD formulation that maximizes oral bioavailability (ideally matching the performance of a belinostat oral solution) and defining critical performance attributes for formulation optimization. The in vivo pharmacokinetic study with beagle dogs demonstrated that 1 of the 3 SDDs (PVP K30 SDD) matched the performance of the oral solution. In vitro data coupled with in silico modeling elucidated differences among the SDDs and supported the hypothesis that absorption of belinostat in the small intestine from the other 2 SDDs (PVP VA64 and HPMCAS-M) may be limited by dissolution rate or reduced drug activity (maximum concentration) in the presence of polymer. It was concluded that drug concentration in the stomach before emptying into the proximal intestine is a key factor for maximizing in vivo performance.
Collapse
Affiliation(s)
- Aaron Stewart
- Drug Product Development and Innovation, Lonza Pharma and Biotech, Bend, Oregon 97703
| | - Ian Yates
- Dosage Form and Delivery Services, Lonza Pharma and Biotech, Bend, Oregon 97703
| | - Deanna Mudie
- Drug Product Development and Innovation, Lonza Pharma and Biotech, Bend, Oregon 97703.
| | - Perrine Pivette
- Onxeo, 49 Boulevard du Général Martial Valin, Paris 75015, France
| | - Aaron Goodwin
- Drug Product Development and Innovation, Lonza Pharma and Biotech, Bend, Oregon 97703
| | - Alyssa Sarmiento
- Dosage Form and Delivery Services, Lonza Pharma and Biotech, Bend, Oregon 97703
| | - Marcus Winter
- Dosage Form and Delivery Services, Lonza Pharma and Biotech, Bend, Oregon 97703
| | - Michael Morgen
- Drug Product Development and Innovation, Lonza Pharma and Biotech, Bend, Oregon 97703
| | - David Vodak
- Drug Product Development and Innovation, Lonza Pharma and Biotech, Bend, Oregon 97703
| |
Collapse
|
7
|
|
8
|
Morgen M, Saxena A, Chen XQ, Miller W, Nkansah R, Goodwin A, Cape J, Haskell R, Su C, Gudmundsson O, Hageman M, Kumar A, Chowan GS, Rao A, Holenarsipur VK. Lipophilic salts of poorly soluble compounds to enable high-dose lipidic SEDDS formulations in drug discovery. Eur J Pharm Biopharm 2017; 117:212-223. [PMID: 28438550 DOI: 10.1016/j.ejpb.2017.04.021] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2016] [Revised: 03/16/2017] [Accepted: 04/20/2017] [Indexed: 10/19/2022]
Abstract
Self-emulsifying drug delivery systems (SEDDS) have been used to solubilize poorly water-soluble drugs to improve exposure in high-dose pharmacokinetic (PK) and toxicokinetic (TK) studies. However, the absorbable dose is often limited by drug solubility in the lipidic SEDDS vehicle. This study focuses on increasing solubility and drug loading of ionizable drugs in SEDDS vehicles using lipophilic counterions to prepare lipophilic salts of drugs. SEDDS formulations of two lipophilic salts-atazanavir-2-naphthalene sulfonic acid (ATV-2-NSA) and atazanavir-dioctyl sulfosuccinic acid (ATV-Doc)-were characterized and their performance compared to atazanavir (ATV) free base formulated as an aqueous crystalline suspension, an organic solution, and a SEDDS suspension, using in vitro, in vivo, and in silico methods. ATV-2-NSA exhibited ∼6-fold increased solubility in a SEDDS vehicle, allowing emulsion dosing at 12mg/mL. In rat PK studies at 60mg/kg, the ATV-2-NSA SEDDS emulsion had comparable exposure to the free-base solution, but with less variability, and had better exposure at high dose than aqueous suspensions of ATV free base. Trends in dose-dependent exposure for various formulations were consistent with GastroPlus™ modeling. Results suggest use of lipophilic salts is a valuable approach for delivering poorly soluble compounds at high doses in Discovery.
Collapse
Affiliation(s)
- Michael Morgen
- Bend Research Inc., a division of Capsugel, 64550 Research Road, Bend, OR 97703, USA.
| | - Ajay Saxena
- Biopharmaceutics, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560099, India
| | - Xue-Qing Chen
- Discovery Pharmaceutics, Bristol-Myers Squibb USA, Bristol-Myers Squibb Pharmaceutical Research Institute, Route 206, Province Line Road P.O. Box 4000, Princeton, NJ 08543, USA
| | - Warren Miller
- Bend Research Inc., a division of Capsugel, 64550 Research Road, Bend, OR 97703, USA
| | - Richard Nkansah
- Bend Research Inc., a division of Capsugel, 64550 Research Road, Bend, OR 97703, USA
| | - Aaron Goodwin
- Bend Research Inc., a division of Capsugel, 64550 Research Road, Bend, OR 97703, USA
| | - Jon Cape
- Bend Research Inc., a division of Capsugel, 64550 Research Road, Bend, OR 97703, USA
| | - Roy Haskell
- Discovery Pharmaceutics, Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb USA, 5 Research Pkwy, Wallingford, CT 06492, USA
| | - Ching Su
- Discovery Pharmaceutics, Bristol-Myers Squibb USA, Bristol-Myers Squibb Pharmaceutical Research Institute, Route 206, Province Line Road P.O. Box 4000, Princeton, NJ 08543, USA
| | - Olafur Gudmundsson
- Discovery Pharmaceutics, Bristol-Myers Squibb USA, Bristol-Myers Squibb Pharmaceutical Research Institute, Route 206, Province Line Road P.O. Box 4000, Princeton, NJ 08543, USA
| | - Michael Hageman
- Discovery Pharmaceutics, Bristol-Myers Squibb USA, Bristol-Myers Squibb Pharmaceutical Research Institute, Route 206, Province Line Road P.O. Box 4000, Princeton, NJ 08543, USA
| | - Anoop Kumar
- Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560099, India
| | - Gajendra Singh Chowan
- Biopharmaceutics, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560099, India
| | - Abhijith Rao
- Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560099, India
| | - Vinay K Holenarsipur
- Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560099, India
| |
Collapse
|
9
|
Morgen M, Jöst C, Malz M, Janowski R, Niessing D, Klein CD, Gunkel N, Miller AK. Spiroepoxytriazoles Are Fumagillin-like Irreversible Inhibitors of MetAP2 with Potent Cellular Activity. ACS Chem Biol 2016; 11:1001-11. [PMID: 26686773 DOI: 10.1021/acschembio.5b00755] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Methionine aminopeptidases (MetAPs) are responsible for the cotranslational cleavage of initiator methionines from nascent proteins. The MetAP2 subtype is up-regulated in many cancers, and selective inhibition of MetAP2 suppresses both vascularization and growth of tumors in animal models. The natural product fumagillin is a selective and potent irreversible inhibitor of MetAP2, and semisynthetic derivatives of fumagillin have shown promise in clinical studies for the treatment of cancer, and, more recently, for obesity. Further development of fumagillin derivatives has been complicated, however, by their generally poor pharmacokinetics. In an attempt to overcome these limitations, we developed an easily diversifiable synthesis of a novel class of MetAP2 inhibitors that were designed to mimic fumagillin's molecular scaffold but have improved pharmacological profiles. These substances were found to be potent and selective inhibitors of MetAP2, as demonstrated in biochemical enzymatic assays against three MetAP isoforms. Inhibitors with the same relative and absolute stereoconfiguration as fumagillin displayed significantly higher activity than their diastereomeric and enantiomeric isomers. X-ray crystallographic analysis revealed that the inhibitors covalently modify His231 in the MetAP2 active site via ring-opening of a spiroepoxide. Biochemically active substances inhibited the growth of endothelial cells and a MetAP2-sensitive cancer cell line, while closely related inactive isomers had little effect on the proliferation of either cell type. These effects correlated with altered N-terminal processing of the protein 14-3-3-γ. Finally, selected substances were found to have improved stabilities in mouse plasma and microsomes relative to the clinically investigated fumagillin derivative beloranib.
Collapse
Affiliation(s)
- Michael Morgen
- Cancer
Drug Development Group, German Cancer Research Center (DKFZ), Im Neunheimer
Feld 280, D-69120 Heidelberg, Germany
| | - Christian Jöst
- Medicinal
Chemistry, Institute of Pharmacy and Molecular Biotechnology (IPMB), Heidelberg University, Im Neuenheimer Feld 364, D-69120 Heidelberg, Germany
| | - Mona Malz
- Cancer
Drug Development Group, German Cancer Research Center (DKFZ), Im Neunheimer
Feld 280, D-69120 Heidelberg, Germany
| | - Robert Janowski
- Institute
of Structural Biology, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), D-85764 Neuherberg, Germany
| | - Dierk Niessing
- Institute
of Structural Biology, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), D-85764 Neuherberg, Germany
- Biomedical Center of the Ludwig-Maximilians-Universität München, D-82152 Planegg-Martinsried, Germany
| | - Christian D. Klein
- Medicinal
Chemistry, Institute of Pharmacy and Molecular Biotechnology (IPMB), Heidelberg University, Im Neuenheimer Feld 364, D-69120 Heidelberg, Germany
| | - Nikolas Gunkel
- Cancer
Drug Development Group, German Cancer Research Center (DKFZ), Im Neunheimer
Feld 280, D-69120 Heidelberg, Germany
| | - Aubry K. Miller
- Cancer
Drug Development Group, German Cancer Research Center (DKFZ), Im Neunheimer
Feld 280, D-69120 Heidelberg, Germany
| |
Collapse
|
10
|
Brox D, Comba P, Herten DP, Kimmle E, Morgen M, Rühl CL, Rybina A, Stephan H, Storch G, Wadepohl H. Cu(II)-selective bispidine-dye conjugates. J Inorg Biochem 2015; 148:78-83. [PMID: 26048430 DOI: 10.1016/j.jinorgbio.2015.05.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Revised: 05/15/2015] [Accepted: 05/15/2015] [Indexed: 12/21/2022]
Abstract
The substitution of tetradentate bispidine ligands with rhodamine and cyanine dye molecules, coupled to an amine donor, forming an amide as potential fifth donor, is described. Bispidines are known to lead to very stable Cu(II) complexes, and the coordination to Cu(II) was expected to efficiently quench the fluorescence of dye molecules. However, at physiological pH the amide is not coordinated, as shown by titration experiments and crystallographic structural data of three possible isomers of these complexes. This may be due to the specific cavity shape of bispidines and the Jahn-Teller lability of the Cu(II) center. While Cu(II) coordination in aqueous solution leads to efficient fluorescence quenching, experiments show that the complex stabilities are not large enough for Cu(II) sensing in biological media, and possibilities are discussed, how this may be achieved by optimized bispidine-dye conjugates.
Collapse
Affiliation(s)
- Dominik Brox
- Universität Heidelberg, Bioquant, Heidelberg, Germany
| | - Peter Comba
- Universität Heidelberg, Anorganisch-Chemisches Institut and Interdisciplinary Center for Scientific Computing (IWR), Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany.
| | | | - Esther Kimmle
- Universität Heidelberg, Bioquant, Heidelberg, Germany
| | - Michael Morgen
- Universität Heidelberg, Anorganisch-Chemisches Institut and Interdisciplinary Center for Scientific Computing (IWR), Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Carmen L Rühl
- Universität Heidelberg, Anorganisch-Chemisches Institut and Interdisciplinary Center for Scientific Computing (IWR), Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Arina Rybina
- Universität Heidelberg, Bioquant, Heidelberg, Germany
| | - Holger Stephan
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, PF 510119, 01314 Dresden, Germany
| | - Golo Storch
- Universität Heidelberg, Bioquant, Heidelberg, Germany
| | - Hubert Wadepohl
- Universität Heidelberg, Anorganisch-Chemisches Institut and Interdisciplinary Center for Scientific Computing (IWR), Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| |
Collapse
|
11
|
Comba P, Hunoldt S, Morgen M, Pietzsch J, Steinbach J, Stephan H, Walther M. Bispidines as a platform for targeted multimodal imaging. Nucl Med Biol 2014. [DOI: 10.1016/j.nucmedbio.2014.05.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Comba P, Hunoldt S, Morgen M, Pietzsch J, Stephan H, Wadepohl H. Optimization of Pentadentate Bispidines as Bifunctional Chelators for 64Cu Positron Emission Tomography (PET). Inorg Chem 2013; 52:8131-43. [DOI: 10.1021/ic4008685] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Peter Comba
- Anorganisch-Chemisches Institut, Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany
| | - Sebastian Hunoldt
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, D-01314 Dresden, Germany
| | - Michael Morgen
- Anorganisch-Chemisches Institut, Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany
| | - Jens Pietzsch
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, D-01314 Dresden, Germany
- Department of Chemistry and Food Chemistry, University of Technology Dresden, D-01062 Dresden, Germany
| | - Holger Stephan
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, D-01314 Dresden, Germany
| | - Hubert Wadepohl
- Anorganisch-Chemisches Institut, Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany
| |
Collapse
|
13
|
Comba P, Morgen M, Wadepohl H. Tuning of the Properties of Transition-Metal Bispidine Complexes by Variation of the Basicity of the Aromatic Donor Groups. Inorg Chem 2013; 52:6481-501. [DOI: 10.1021/ic4004214] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Peter Comba
- Anorganisch-Chemisches Institut, Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany
| | - Michael Morgen
- Anorganisch-Chemisches Institut, Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany
| | - Hubert Wadepohl
- Anorganisch-Chemisches Institut, Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany
| |
Collapse
|
14
|
Comba P, Emmerling F, Jakob M, Kraus W, Kubeil M, Morgen M, Pietzsch J, Stephan H. Copper(ii) chemistry of the functionalized macrocycle cyclam tetrapropionic acid. Dalton Trans 2013; 42:6142-8. [DOI: 10.1039/c2dt32356g] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
15
|
Sieb D, Schuhen K, Morgen M, Herrmann H, Wadepohl H, Lucas NT, Baker RW, Enders M. Synthesis and Complexation Behavior of Indenyl and Cyclopentadienyl Ligands Functionalized with a Naphthyridine Unit. Organometallics 2011. [DOI: 10.1021/om2009638] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- David Sieb
- Anorganisch-Chemisches Institut der Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Katrin Schuhen
- Anorganisch-Chemisches Institut der Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Michael Morgen
- Anorganisch-Chemisches Institut der Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Heike Herrmann
- Anorganisch-Chemisches Institut der Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Hubert Wadepohl
- Anorganisch-Chemisches Institut der Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Nigel T. Lucas
- Department of Chemistry, University of Otago, Dunedin 9054, New Zealand
| | - Robert W. Baker
- School of Chemistry, University of Sydney, NSW 2006, Australia
| | - Markus Enders
- Anorganisch-Chemisches Institut der Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| |
Collapse
|
16
|
Morgen M, Bloom C, Beyerinck R, Bello A, Song W, Wilkinson K, Steenwyk R, Shamblin S. Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug. Pharm Res 2011; 29:427-40. [PMID: 21863477 PMCID: PMC3264876 DOI: 10.1007/s11095-011-0558-7] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2011] [Accepted: 08/02/2011] [Indexed: 12/01/2022]
Abstract
Purpose To demonstrate drug/polymer nanoparticles can increase the rate and extent of oral absorption of a low-solubility, high-permeability drug. Methods Amorphous drug/polymer nanoparticles containing celecoxib were prepared using ethyl cellulose and either sodium caseinate or bile salt. Nanoparticles were characterized using dynamic light scattering, transmission and scanning electron microscopy, and differential scanning calorimetry. Drug release and resuspension studies were performed using high-performance liquid chromatography. Pharmacokinetic studies were performed in dogs and humans. Results A physical model is presented describing the nanoparticle state of matter and release performance. Nanoparticles dosed orally in aqueous suspensions provided higher systemic exposure and faster attainment of peak plasma concentrations than commercial capsules, with median time to maximum drug concentration (Tmax) of 0.75 h in humans for nanoparticles vs. 3 h for commercial capsules. Nanoparticles released celecoxib rapidly and provided higher dissolved-drug concentrations than micronized crystalline drug. Nanoparticle suspensions are stable for several days and can be spray-dried to form dry powders that resuspend in water. Conclusions Drug/polymer nanoparticles are well suited for providing rapid oral absorption and increased bioavailability of BCS Class II drugs.
Collapse
Affiliation(s)
- Michael Morgen
- Bend Research Inc., 64550 Research Road, Bend, Oregon 97701, USA.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Affiliation(s)
- Michael Morgen
- University of Heidelberg, Department of Organic Chemistry, INF 270, D-69120 Heidelberg, Germany
| | - Sebastian Bretzke
- University of Heidelberg, Department of Organic Chemistry, INF 270, D-69120 Heidelberg, Germany
| | - Pengfei Li
- University of Heidelberg, Department of Organic Chemistry, INF 270, D-69120 Heidelberg, Germany
| | - Dirk Menche
- University of Heidelberg, Department of Organic Chemistry, INF 270, D-69120 Heidelberg, Germany
| |
Collapse
|
18
|
Affiliation(s)
- Michael Morgen
- Microelectronics Research Center, University of Texas, Austin, Texas 78712; e-mail:
| | - E. Todd Ryan
- Microelectronics Research Center, University of Texas, Austin, Texas 78712; e-mail:
| | - Jie-Hua Zhao
- Microelectronics Research Center, University of Texas, Austin, Texas 78712; e-mail:
| | - Chuan Hu
- Microelectronics Research Center, University of Texas, Austin, Texas 78712; e-mail:
| | - Taiheui Cho
- Microelectronics Research Center, University of Texas, Austin, Texas 78712; e-mail:
| | - Paul S. Ho
- Microelectronics Research Center, University of Texas, Austin, Texas 78712; e-mail:
| |
Collapse
|
19
|
Morgen M, Rhee SH, Zhao JH, Malik I, Ryan T, Ho HM, Plano MA, Ho P. Comparison of Crystalline Phase Transitions in Fluorniated vs Nonfluorinated Parylene Thin Films. Macromolecules 1999. [DOI: 10.1021/ma991049w] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Michael Morgen
- Institute for Materials Science, University of Texas, Austin, Texas 78712; SEMATECH, 2706 Montopolis Dr., Austin, Texas 78741; and Novellus Systems, San Jose, California 95134
| | - Seung-Hyun Rhee
- Institute for Materials Science, University of Texas, Austin, Texas 78712; SEMATECH, 2706 Montopolis Dr., Austin, Texas 78741; and Novellus Systems, San Jose, California 95134
| | - Jie-Hua Zhao
- Institute for Materials Science, University of Texas, Austin, Texas 78712; SEMATECH, 2706 Montopolis Dr., Austin, Texas 78741; and Novellus Systems, San Jose, California 95134
| | - Irfan Malik
- Institute for Materials Science, University of Texas, Austin, Texas 78712; SEMATECH, 2706 Montopolis Dr., Austin, Texas 78741; and Novellus Systems, San Jose, California 95134
| | - Todd Ryan
- Institute for Materials Science, University of Texas, Austin, Texas 78712; SEMATECH, 2706 Montopolis Dr., Austin, Texas 78741; and Novellus Systems, San Jose, California 95134
| | - Huei-Min Ho
- Institute for Materials Science, University of Texas, Austin, Texas 78712; SEMATECH, 2706 Montopolis Dr., Austin, Texas 78741; and Novellus Systems, San Jose, California 95134
| | - Mary Anne Plano
- Institute for Materials Science, University of Texas, Austin, Texas 78712; SEMATECH, 2706 Montopolis Dr., Austin, Texas 78741; and Novellus Systems, San Jose, California 95134
| | - Paul Ho
- Institute for Materials Science, University of Texas, Austin, Texas 78712; SEMATECH, 2706 Montopolis Dr., Austin, Texas 78741; and Novellus Systems, San Jose, California 95134
| |
Collapse
|
20
|
Morgen M, Price W, Ludowise P, Chen Y. Tensor analysis of femtosecond Raman induced polarization spectroscopy: Application to the study of rotational coherence. J Chem Phys 1995. [DOI: 10.1063/1.468931] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Chen Y, Hunziker L, Ludowise P, Morgen M. Femtosecond transient stimulated emission pumping studies of ozone visible photodissociation. J Chem Phys 1992. [DOI: 10.1063/1.463102] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|